Inactive Instrument

Vilacto Bio Inc.

Equities

VIBI

US92686M1099

Biotechnology & Medical Research

Vilacto Bio Inc. Reports Earnings Results for the Full Year Ended March 31, 2019

July 10, 2019 at 01:41 pm EDT

Vilacto Bio Inc. announced earnings results for the full year ended March 31, 2019. For the full year, the company announced sales was USD 4,894 compared to USD 1,429 a year ago. Operating loss was USD 970,039 compared to USD 381,545 a year ago. Net loss was USD 6.854 million compared to USD 893,117 a year ago. Basic loss per share was USD 0.05 compared to USD 0.01 a year ago.

Latest news about Vilacto Bio Inc.

Vilacto Bio Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019	19-08-19	CI
Vilacto Bio Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	19-07-10	CI
Vilacto Bio Inc. Plans to Introduce 2 New Products	19-04-09	CI
Vilacto Bio Offering Natural Alternatives to Strong Drugs in the Psoriasis and Diabetics Market	19-04-09	CI
Vilacto Bio Inc. Informs its Patent Application for LACTOACTIVE to be Issued in Near Future	19-03-15	CI
Vilacto Bio Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-02-19	CI
Vilacto Bio Secured Patent Applications for Lactoactive®	18-11-30	CI
Vilacto Bio Inc. Reports Earnings Results for the Second Quarter and Half Year Ended September 30, 2018	18-11-19	CI
Vilacto Bio Inc. cancelled the acquisition of Pharma GP APS from 9 Heroes APS.	18-11-07	CI
Vilacto Bio Inc. Announces Launch of Carmen Electra by Vilact®	18-10-01	CI
Vilacto Bio Inc. announced that it expects to receive $0.17 million in funding from Auctus Private Equity Management, Inc.	18-02-25	CI
Vilacto Bio Inc. announced that it expects to receive $0.13 million in funding from EMA Financial LLC	18-02-22	CI
Vilacto Bio Inc. Begins Development of the Vilacto Bio Skincare Knowledge Center	18-01-18	CI
Vilacto Bio Inc. Retains The Equity Group Inc. to Facilitate All Aspects of Investor Relations and Financial Communications	17-11-17	CI
Vilacto Bio Inc. in Final Stage of Developing Anti-Aging Products	17-11-10	CI
Vilacto Bio Inc. Upgrades its Production Facility	17-07-14	CI
Vilacto Bio Inc. entered into a stock purchase agreement to acquire Pharma GP APS from 9 Heroes APS for $6 million.	17-04-19	CI
Zlato Inc. Announces Management Changes	17-03-03	CI
Gert Andersen acquired 83.33% stake in Zlato Inc. from Dana Gallovicova for $0.13 million.	17-02-27	CI
Vilacto Bio Inc. Auditor Raises 'Going Concern' Doubt	16-01-03	CI
Zlato Inc. has completed an IPO in the amount of $0.05 million.	13-10-31	CI
Zlato Inc. has completed an IPO in the amount of $0.05 million.	13-10-31	CI
Zlato Inc. has filed an IPO in the amount of $0.05 million.	13-08-15	CI

Chart Vilacto Bio Inc.

Duration

Period

More charts

Company Profile

Vilacto Bio Inc., formerly Zlato Inc., is a biotechnology company engaged in the business of skincare products. The Company has developed Lactoactive, which is processing of colostrum combined with hyaluronic acid. Lactoactive contains hyaluronic acid, which penetrates the skin, regenerates damaged skin cells and restores elasticity. The Company provides treatment for various diseases, including inflammatory disorders & anti-inflammatory treatments, immune system factors, psoriasis, vitiligo, autoimmune related skin conditions, systemic lupus erythematosus (SLE) disease, blistering skin disease and diabetic ulcers disease. The Company sells its products under the name Vilact. The Company also sells its products through its Website www.vilactobio.com. The Company has operations in New York in the United States, Naestved in Denmark and Lithuania.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+19.94%	42.68B
IQVIA HOLDINGS INC.	-2.12%	42.4B
LONZA GROUP AG	+45.15%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.32%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+30.53%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.72%	11.95B
BIO-TECHNE CORPORATION	-3.65%	11.55B

Other Biotechnology & Medical Research